If, when and how does an investment in IP pay off? You will receive answers to these questions from our partners Dr. Christiane Maxien and Dr. Christian Kirchner in the current issue of Plattform Life Sciences.
It always starts with the idea of improving the health of the individual through personalized medical technology. If this succeeds, sooner or later the questions will arise: How can I protect this idea - is it also patentable? This topic is often relevant for many, especially when it comes to data-based innovations....
The mission of the Life Sciences platform from the GoingPublic publishing house is the cross-media connection (magazine - web - event - network) of the life sciences with knowledge and networks from corporate finance and the capital market. According to its own statements, GoingPublic Media AG is one of the leading media houses for corporate financing and investment issues. As part of its cross-media platform approach, the group publishes around 40 magazine issues per year and operates three web platforms, including the Life Sciences platform, in connection with online newsletters and social media presences.
Read the article (in German) here.
Here is the link to the complete e-magazine: https://www.goingpublic.de/aktuelles-epaper-lifesciences/
The term of European patents is clearly defined in Art. 63 EPC: "The term of the European patent shall be 20 years from the date of filing of the application." However, a patent only develops its protective effect from the date of grant and not from the filing date. This leads to a considerably shortened period of protection.
In the first issue of this year's life sciences magazine BIOspectrum, our partners Dr. Erich Fritsche and Dr. Mathias Ricker discuss in this context strategies for effective renewal of patents. You can download the text of the article, which is in German, here.
BIO Spectrum is the publication medium of the (German) Society for Biochemistry and Molecular Biology (Gesellschaft für Biochemie und Molekularbiologie, GBM), the Association for General and Applied Microbiology (Vereinigung für Allgemeine und Angewandte Mikrobiologie, VAAM), the Genetics Society (Gesellschaft für Genetik, GfG) and the German Society for Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, DGPT). Every two months, the magazine gives around 15,000 readers an overview of new developments in the life sciences (with a focus on molecular biology, biochemistry, microbiology, genetics and developmental biology) and provides information on current affairs from business and politics. (according to scientific publishing house Springer)
In view of the current discussions on “plausibility”, in particular in the areas of chemistry and life sciences and as background for the upcoming EPO Enlarged Board of Appeal decision G 2/21 we “reload” an earlier article by our partner Holger Tostmann that was first published in the American Chemical Society’s Medicinal Chemistry Letters (ACS Med. Chem. Lett. 2015, 6, 364−366).
For years, two US universities have been struggling over who is entitled to patent protection for the CRISPR/Cas9 technology respectively who invented it (first): on one side are the University of California (UC) and the two Nobel Prize winners Emmanuel Charpentier and Jennifer Doudna, and on the other side are the Board Institute and two scientists, George Church and Feng Zhang.
With her comment "CRISPR/Cas9-Genschere: Nobelpreis und Patentstreit – die zwei Schneiden der Schere?" (literally: CRISPR/Cas9 gene scissors: Nobel Prize and patent dispute - the two edges of the scissors?") in the current issue of the life sciences magazine BIOspektrum, our partner Dr. Christiane Maxien illustrates the different situation of the patent dispute in the US and in Europe. You can download the text of the article, which is in German, here.
BIO Spectrum is the publication medium of the (German) Society for Biochemistry and Molecular Biology (Gesellschaft für Biochemie und Molekularbiologie, GBM), the Association for General and Applied Microbiology (Vereinigung für Allgemeine und Angewandte Mikrobiologie, VAAM), the Genetics Society (Gesellschaft für Genetik, GfG) and the German Society for Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, DGPT). Every two months, the magazine gives around 15,000 readers an overview of new developments in the life sciences (with a focus on molecular biology, biochemistry, microbiology, genetics and developmental biology) and provides information on current affairs from business and politics. (according to scientific publishing house Springer)
.
